儿童低磷性佝偻病的诊治新进展

徐钰艳; 朱柳燕; 邵洁

doi:10.11852/zgetbjzz2020-1413

PDF(683 KB)

中国儿童保健杂志 ›› 2021, Vol. 29 ›› Issue (11) : 1213-1217. DOI: 10.11852/zgetbjzz2020-1413

综述

儿童低磷性佝偻病的诊治新进展

徐钰艳, 朱柳燕, 邵洁

作者信息 +

Research advances on the diagnosis and treatment of hypophosphatemic rickets in children

XU Yu-yan, ZHU Liu-yan, SHAO Jie

Author information +

文章历史 +

摘要

低磷性佝偻病(HR)又称家族性低磷血症,是以低磷血症及肾脏磷酸盐丢失为特征,主要表现为骨矿化障碍的遗传性疾病。它包括一组表型相似但基因型、遗传模式和病因不同的疾病,最常见的HR是X连锁显性低磷血症佝偻病(XLH)。不常见的HR可由常染色体显性或隐性遗传等原因引起。成纤维细胞生长因子23(FGF23)基因的激活突变和调控FGF-23基因的失活突变已被确认,并被证实与这些紊乱的发病机制有关。本文就HR的病理生理、发病机制、临床表现、诊断和治疗等方面作一综述,为佝偻病的鉴别和精准诊治提供参考和指导。

Abstract

Hypophosphatemic rickets(HR),also known as familial hypophosphatemia,is a hereditary disease characterized by hypophosphatemia and renal phosphate loss,mainly manifested as bone mineralization disorders. It includes a group of diseases with similar phenotypes but different genotypes,hereditary patterns and etiologies. The most common HR is X-linked dominant hypophosphatemic rickets(XLH). Uncommon HR may be caused by autosomal dominant or recessive inheritance. Activation mutation of fibroblast growth factor 23(FGF23) gene and inactivation mutation of regulation gene involved in FGF-23 regulation have been confirmed and proved to be related to the pathogenesis of these disorders. The pathophysiology,pathogenesis,clinical manifestations,diagnosis and treatment of HR will be reviewed in this paper reviews.

导出引用

徐钰艳, 朱柳燕, 邵洁. 儿童低磷性佝偻病的诊治新进展[J]. 中国儿童保健杂志. 2021, 29(11): 1213-1217 https://doi.org/10.11852/zgetbjzz2020-1413

XU Yu-yan, ZHU Liu-yan, SHAO Jie. Research advances on the diagnosis and treatment of hypophosphatemic rickets in children[J]. Chinese Journal of Child Health Care. 2021, 29(11): 1213-1217 https://doi.org/10.11852/zgetbjzz2020-1413

中图分类号： R725.9

参考文献

[1] Michalus I,Rusińska A. Rare,genetically conditioned forms of rickets:Differential diagnosis and advances in diagnostics and treatment[J]. Clin Genet,2018,94(1) :103-114.
[2] Lambert AS,Linglart A. Hypocalcaemic and hypophosphatemic rickets[J]. Best Pract Res Clin Endocrinol Metab,2018,32(4):455-476.
[3] Robinson ME,AlQuorain H,Murshed M,et al. Mineralized tissues in hypophosphatemic rickets[J]. Pediatr Nephrol,2020,35(10):1843-1854.
[4] Goldsweig BK,Carpenter TO. Hypophosphatemic rickets:lessons from disrupted FGF23 control of phosphorus homeostasis[J]. Curr Osteoporos Rep,2015,13(2):88-97.
[5] Blaine J,Chonchol M,Levi M. Renal control of calcium,phosphate,and magnesium homeostasis[J]. Clin J Am Soc Nephrol,2015,10(7):1257-72.
[6] Kinoshita Y,Fukumoto S. X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases:prospect for new treatment[J]. Endocr Rev,2018,39(3):274-291.
[7] Christov M, Jüppner H. Phosphate homeostasis disorders[J]. Best Pract Res Clin Endocrinol Metab,2018,32(5):685-706.
[8] Bergwitz C,Miyamoto KI. Hereditary hypophosphatemic rickets with hypercalciuria:pathophysiology,clinical presentation,diagnosis and therapy[J]. Pflugers Arch,2019,471(1):149-163.
[9] Fuente R, Gil-Peña H, Claramunt-Taberner D,et al. X-linked hypophosphatemia and growth[J]. Rev Endocr Metab Disord,2017,18(1):107-115.
[10] Carpenter TO,Shaw NJ,Portale AA,et al.Rickets[J].Nat Rev Dis Primers,2017,3:17101.
[11] Menon LP,Weinstein RS.Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets:A review of the role of iron.[J].Bone,2020,131:115-137.
[12] Haffner D,Emma F,Eastwood DM,et al.Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia[J].Nat Rev Nephrol,2019,15(7):435-455.
[13] Rafaelsen S,Johansson S,Raeder H,et al.Hereditary hypophosphatemia in Norway:a retrospective population-based study of genotypes,phenotypes,and treatment complications[J].Eur J Endocrinol,2016,174(2):125-136.
[14] Gordon RJ,Levine MA.Burosumab treatment of children with X-linked hypophosphataemic rickets[J].Lancet,2019,393(10189):2364-2366.
[15] Bitzan M,Goodyer PR.Hypophosphatemic rickets[J].Pediatr Clin North Am,2019,66(1):179-207.
[16] Farrow EG,Yu X,Summers LJ,etal.Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice[J]. Proc Natl Acad Sci U S A,2011,108(46):1146-1155.
[17] Imel EA,Liu Z,Coffman M,et al. Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets[J]. J Bone Miner Res,2020,35(2):231-238
[18] Razali NN,Hwu TT,Thilakavathy K.Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets[J].J Pediatr Endocrinol Metab,2015,28(9-10):1009-1017.
[19] Oheim R,Zimmerman K,Maulding ND,et al. Human heterozygous ENPP1 deficiency is associated with early onset osteoporosis,a phenotype recapitulated in a mouse model of enpp1 deficiency[J]. J Bone Miner Res,2020,35(3):528-539.
[20] Kotwal A,Ferrer A,Kumar R,et al. Clinical and biochemical phenotypes in a family with ENPP1 mutations[J]. J Bone Miner Res,2020,35(4):662-670.
[21] Asch S,Sugarman JL. Epidermal nevus syndromes:New insights into whorls and swirls[J]. Pediatric Dermatol,2018,35:21-29.
[22] Avitan-Hersh E,Tatur S,Indelman M,et al. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23[J]. J Clin Endocrinol Metab,2014,99(1):132-136.
[23] Park PG,Park E,Hyun HS,et al. Cutaneous skeletal hypophosphatemia syndrome in association with a mosaic HRAS mutation[J]. Ann Clin Lab Sci,2018,48(5):665-669.
[24] Pal R,Dutta P,Mukherjee KK,et al. Acromegaly with hypophosphataemia:McCune-Albright syndrome[J]. BMJ Case Rep,2017:bcr2017221827.
[25] Obo T,Koriyama N,Tokito A,et al. Neurofibromatosis type 1 associated with hypophosphatemic osteomalacia due to hypersecretion of fibroblast growth factor 23:a case report[J]. J Med Case Rep,2020,14(1):56.
[26] Rothenbuhler A,Schnabel D,Hogler W,et al.Diagnosis,treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)[J].Metabolism,2020,103s:153892.
[27] Chesher D,Oddy M,Darbar U,et al.Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations[J].J Inherit Metab Dis,2018,41(5):865-876.
[28] Vega RA,Opalak C,Harshbarger RJ,et al.Hypophosphatemic rickets and craniosynostosis:a multicenter case series[J].J Neurosurg Pediatr,2016,17(6):694-700.
[29] Rothenbuhler A,Fadel N,Debza Y,et al.High incidence of cranial synostosis and chiari I malformation in children with X-Linked hypophosphatemic rickets (XLHR)[J].J Bone Miner Res,2019,34(3):490-496.
[30] Brachet C,Mansbach AL,Clerckx A,et al.Hearing loss is part of the clinical picture of ENPP1 loss of function mutation[J].Horm Res Paediatr,2014,81(1):63-66.
[31] Lempicki M,Rothenbuhler A,Merzoug V,et al.Magnetic resonance imaging features as surrogate markers of X-Linked hypophosphatemic rickets activity.[J].Horm Res Paediatr,2017,87(4):244-253.
[32] Keskin M,Savas-Erdeve S,Sagsak E,et al.Risk factors affecting the development of nephrocalcinosis,the most common complication of hypophosphatemic rickets[J].J Pediatr Endocrinol Metab,2015,28(11-12):1333-1337.
[33] Insogna KL,Briot K,Imel EA,et al.A Randomized,double-blind,placebo-controlled,phase 3 trial evaluating the efficacy of burosumab,an anti-FGF23 antibody,in adults with X-Linked Hypophosphatemia:Week 24 primary analysis[J].J Bone Miner Res,2018,33(8):1383-1393.
[34] Lamb YN.Burosumab:First global approval[J].Drugs,2018,78(6):707-714.
[35] Kapelari K,Kohle J,Kotzot D,et al. Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets[J].J Clinton Endocrinol Metab,2015,100(9):3388-3392.
[36] Meyerhoff N,Haffner D,Staude H,et al.Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets[J].Pediatr Nephrol,2018,33(3):447-456.
[37] Sharkey MS,Grunseich K,Carpenter TO.Contemporary medical and surgical management of X-linked hypophosphatemic rickets[J].J Am Acad Orthop Surg,2015,23(7):433-442.